Why the study?
The optimal use of the cardiovascular polypill (ASA, atorvastatin, and ramipril) in secondary prevention after acute myocardial infarction lacked global expert consensus.
A global Delphi consensus supports the early initiation of a cardiovascular polypill (acetylsalicylic acid, atorvastatin, and ramipril) for secondary prevention post-acute coronary syndrome, ideally at hospital discharge or first follow-up.
Supports early polypill use at discharge for post-ACS secondary prevention; extends trial data with global expert consensus.
Background: The SECURE trial demonstrated that the cardiovascular (CV)-polypill (acetylsalicylic acid [ASA] + atorvastatin + ramipril) reduces CV mortality by 33% in patients with acute myocardial infarction compared to standard care. The 2023 ACS ESC Guidelines recommend the polypill to improve outcomes and adherence. Objective: This study aims to establish a global consensus on the optimal use of the CV-polypill in secondary prevention. Methods: A two-round, modified Delphi method was used, featuring a 30-statement evidence-based questionnaire validated by eight renowned cardiologists. Fifty clinicians from 19 countries in Europe, Latin America, and Asia were invited to join the Delphi panel. Panelists ranked responses using a three-point Likert scale for agreement and importance. Consensus was defined as ≥80% agreement or rating statements 'very important' or 'important'. Statements without consensus after the first round were refined with evidence and feedback in the second round. Remaining disagreements were resolved in a face-to-face meeting. Descriptive statistics were applied. Results: Response rate was 76% (round 1) and 74% (round 2); 82% were cardiologists, with 74% frequently recommending the CV-polypill. Consensus was achieved on 93.3% of statements. Research showing a 24% relative risk reduction in major adverse CV events over a median of 3 years with the CV-polypill post-acute myocardial infarction, compared to usual care, reached 97.4% agreement for clinical implementation, and a 100% consensus supported polypill use at hospital discharge or first follow-up visits; 81.1% agreed on a prompt initiation after patient stabilization. There was agreement on algorithms for initiating (97.3%), considering patient preferences (97.4%) to the polypill and its cost savings over usual care (89.5%). Conclusion: The Delphi consensus on real-world use of a CV polypill (ASA, atorvastatin, and ramipril) for secondary prevention post-acute coronary syndrome supports early initiation (within 8 days or at discharge). The findings provide a foundation to inform practice and policy, identifying priorities for further research.
No takes yet. Share an insight, caveat, or question.
Piñeiro et al. (2025) studied Secondary prevention of cardiovascular disease (n=38). Cardiovascular polypill (acetylsalicylic acid, atorvastatin, and ramipril) vs. Standard care was evaluated on Consensus on statements regarding the optimal use of the CV-polypill in secondary prevention. A global expert Delphi panel reached a 93.3% consensus supporting the early initiation of a cardiovascular polypill (ASA, atorvastatin, and ramipril) for secondary prevention post-acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: